Dr. Sever is an Associate Professor of Medicine at Harvard Medical School. She leads a laboratory at Massachusetts General Hospital and is a scientific co-founder of Walden Biosciences.
Dr. Sever is an internationally recognized molecular biologist whose research focuses on podocyte biology and molecular mechanisms that underlie kidney diseases. She has authored seminal studies uncovering a previously unrecognized role for the GTPase dynamin in directly regulating the actin cytoskeleton. Her studies pave the way for pharmacological targeting of actin cytoskeleton dynamics in diverse human diseases. Her research has led to several patents for therapeutic and R&D applications. In addition to teaching at Harvard Medical School, she serves on a National Institutes of Health study section and on the NIDDK Strategic Planning group for the future of kidney research.
Dr. Sever was born in Zagreb, Croatia. She earned her B.S. and M.S. in Molecular Biology from Zagreb University. She obtained her Ph.D. in Biochemistry from Zagreb University on the basis of studies performed with Dieter Söll at Yale University, where she was a visiting graduate student. As a post-doctoral fellow with Sandra Schmid at The Scripps Research Institute, she studied how dynamin promotes endocytosis. Since 2002, she has been running an NIH funded laboratory at Massachusetts General Hospital.